Jozef Glasa, Helena Glasová
Introduction of two new molecules from the group of Directly Acting Antivirals (DAAs) –hepatitis C virus (HCV) NS3-4A serine protease inhibitors telaprevir (TVR) and boceprevir (BOC) into the clinical practice in 2012 brought a new standard of treatment for chronic hepatitis C (CHC), which is caused by so far more difficult to treat genotype 1 of HCV (HCV G1). New, highly effective treatment of CHC by triple therapy (3K) uses, besides the medicaments used as yet within the double therapy of CHC (2K) – pegylated interferon alpha (PegIFN) and ribavirin (RBV), also the third medicament from the group of DAAs: TVR (3K-TVR) or BOC (3K-BOC). The necessary pre-requisites of realisation of this innovative treatment comprise ensuring the availability of advanced laboratory diagnostics, right indication of treatment, as well as its overall complex management in an authorised specialised centre.